van Dyck, Christopher H.
Mecca, Adam P.
O’Dell, Ryan S.
Bartlett, Hugh H.
Diepenbrock, Nina G.
Huang, Yiyun
Hamby, Mary E.
Grundman, Michael
Catalano, Susan M.
Caggiano, Anthony O.
Carson, Richard E.
Funding for this research was provided by:
National Institute on Aging (AG057553, AG057553, AG057553, AG057553, AG057553, AG057553, AG057553, AG057553)
Cognition Therapeutics
Article History
Received: 4 August 2023
Accepted: 1 January 2024
First Online: 25 January 2024
Declarations
:
: The informed consent form was required to be signed and dated by the subject and caregiver or study partner before exposure to any study-related procedure, including screening tests for eligibility. The Institutional Review Board (IRB; Yale University IRB, New Haven, CT) reviewed the protocol and the informed consent form. The Investigators were required to conduct all aspects of the study in accordance with all national, state and local laws of applicable Regulatory Authorities.
: Not applicable.
: AOC, SMC, and MEH are current or former employees and shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals outside the submitted work. RSO, YH, and REC have no relevant competing interests or disclosures to report. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Roche, Genentech, UCB, and Cerevel outside the submitted work.